Brief: Royalty Pharma Acquires Remaining Royalty Interest In Roche’S Evrysdi For $240 Million
29/12/2025 22:47
Dec 29 (Reuters) - Royalty Pharma PLC RPRX.O: ROYALTY PHARMA ACQUIRES REMAINING ROYALTY INTEREST IN ROCHE’S EVRYSDI FOR $240 MILLION AND POTENTIAL MILESTONES Source text: ID:nGNXSncJV Further company coverage: RPRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)